Pattern Bioscience Receives FDA Breakthrough Device Designation for Urine ID/AST Panel

Designation advances the company’s Urine (UTI) ID/AST Panel on Pattern’s single-cell microbiology platform. AUSTIN, Texas, September 21, 2026 — Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Urine ID/AST Panel.